百奧賽圖-B(02315.HK)與楊森達成RenLite®授權協議
格隆匯3月8日丨百奧賽圖-B(02315.HK)宣佈，與楊森製藥公司下屬的楊森生物技術公司("楊森")，達成非獨家授權協議。根據授權協議，百奧賽圖授予楊森及其關聯公司全球非獨家許可，使用百奧賽圖專有RenLite®平台及其相關知識產權，以發現、研究、開發和商業化可為數量不限的藥物靶點和適應症服務的全人共輕鏈抗體療法和其他生物療法。該協議由強生創新主導。
RenLite是百奧賽圖全人抗體小鼠RenMice®家族中的一員。RenLite小鼠可產生具有高度特異性、親和力、多樣性和良好成藥性的全人共輕鏈抗體候選分子，用於後續低錯配率和高成功率的雙特異性抗體、多特異性抗體的組裝。這些利用RenLite小鼠開發的抗體組裝成的雙、多特異性抗體具有傳統的抗體結構，並展現出理想的利於下游化學、製造和控制過程(CMC)開發的理化性質。
截至2022年6月30日，百奧賽圖自主研發的全人抗體RenMice®平台已與全球16家生物製藥公司達成授權使用協議，包括德國默克、Xencor、百濟神州、信達生物等。基於全人抗體RenMice技術平台，百奧賽圖抗體發現平台，針對1,000多個潛在成藥靶點開發全人抗體分子。截至2022年6月30日，百奧賽圖已經達成28個抗體分子授權轉讓╱合作開發交易，合作方包括德國默克、華潤生物、南京正大天晴以及榮昌生物等，僅2022年上半年就新增11個交易。2022年下半年，百奧賽圖又與翰森製藥、ADC Therapeutics、泛恩生物等合作方達成抗體分子╱序列授權合作，並與微芯生物、Syncromune等合作方達成臨牀╱臨牀前抗體分子的授權轉讓。百奧賽圖抗體發現平台源源不斷地產出有潛力的抗體分子，並在不同階段與國內外藥企達成合作開發╱分子授權轉讓。
隨着合作方基於RenMice平台授權的研發項目開展，以及各個已授權╱轉讓抗體分子的不斷研發推進，百奧賽圖有望持續獲得可觀的研發里程碑收入和銷售分成等長期收益。隨着公司的抗體技術平台及抗體開發能力進一步得到業界的認可，我們預計會有越來越多的RenMice平台授權合作及抗體分子的授權╱轉讓與合作開發，抗體開發業務也將會成為本公司收入持續增長的強勁來源。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
